CSTL logo

Castle Biosciences, Inc. (CSTL)

$36.78

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CSTL

Market cap

$1.12B

EPS

-0.64

P/E ratio

--

Price to sales

3.03

Dividend yield

--

Beta

0.995316

Price on CSTL

Previous close

$35.48

Today's open

$35.98

Day's range

$34.94 - $36.85

52 week range

$17.72 - $44.28

Profile about CSTL

CEO

Derek J. Maetzold

Employees

761

Headquarters

Friendswood, TX

Exchange

NASDAQ Global Market

Shares outstanding

30549507

Issue type

Common Stock

CSTL industries and sectors

Healthcare

Medical Diagnostics & Screening

News on CSTL

New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus

Decision modeling study shows use of TissueCypher can nearly double appropriate escalation of care for patients with non-dysplastic Barrett's esophagus who later progress to cancer, while substantially reducing overuse of procedures in patients who do not progress FRIENDSWOOD, Texas, Sept. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new decision modeling study showing that the TissueCypher® Barrett's Esophagus test (TSP-9) can help better align Barrett's esophagus (BE) management with a patient's individual risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).

news source

PRNewsWire • Sep 15, 2026

news preview

JAAD Publication Shows Improved Performance of DecisionDx®-SCC

DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient management DecisionDx-SCC's Class 1A (low risk) result demonstrated a 97.3% negative predictive value, supporting confidence in de-escalation decisions, while its Class 2B (highest risk) result identified patients most likely to benefit from adjuvant radiation therapy FRIENDSWOOD, Texas, Sept. 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC).1 DecisionDx-SCC analyzes 40 genes to provide results related to prognosis and response to adjuvant radiation therapy (ART) based on an individual patient's tumor biology.

news source

PRNewsWire • Sep 9, 2026

news preview

SciBase receives additional order from Castle Biosciences, advancing the collaboration

STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences.

news source

PRNewsWire • Sep 8, 2026

news preview

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

news source

Zacks Investment Research • Aug 28, 2026

news preview

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Aug 25, 2026

news preview

Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m.

news source

PRNewsWire • Aug 20, 2026

news preview

Castle Biosciences Approved for Dual Listing on Nasdaq Texas

FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL.

news source

PRNewsWire • Aug 17, 2026

news preview

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.

news source

MarketBeat • Aug 13, 2026

news preview

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Jul 31, 2026

news preview

Castle Biosciences Q2 Earnings Call Highlights

Castle Biosciences NASDAQ: CSTL reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous range of $345 million to $355 million.

news source

MarketBeat • Jul 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Castle Biosciences, Inc.

Open an M1 investment account to buy and sell Castle Biosciences, Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CSTL on M1